DÄ internationalArchiveReferences

Review article

The Diagnosis and Treatment of Hypertriglyceridemia

Dtsch Arztebl Int 2019; 116: 825-32. DOI: 10.3238/arztebl.2019.0825

Parhofer, K G; Laufs, U

1. Jaross W, Assmann G, Bergmann S, et al.: Comparison of risk factors for coronary heart disease in Dresden and Munster. Results of the DRECAN (Dresden Cardiovascular Risk and Nutrition) study and the PROCAM (Prospective Cardiovascular Munster) Study. Eur J Epidemiol. 1994; 10: 307–15 CrossRef MEDLINE
2. Arca M, Borghi C, Pontremoli R, et al.: Hypertriglyceridemia and omega-3 fatty acids: Their often overlooked role in cardiovascular disease prevention. Nutr Metab Cardiovasc Dis 2018; 28: 197–205 CrossRef MEDLINE
3. Grundy SM, Stone NJ, Bailey AL, et al.: 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation. J Am Coll Cardiol 2019; 73: 3168–209 CrossRef MEDLINE
4. Hegele RA, Ginsberg HN, Chapman MJ, et al.: The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol 2014; 2: 655–66 CrossRef
5. Mach F, Baigent C, Catapano AL, et al.: 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2019: doi: 10.1093/eurheartj/ehz455 CrossRef MEDLINE
6.Leiter LA, Lundman P, da Silva PM, et al.: Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. Diabet Med 2011; 28: 1343–51 CrossRef MEDLINE
7. Pedersen SB, Langsted A, Nordestgaard BG: Nonfasting Mild-to-Moderate Hypertriglyceridemia and Risk of Acute Pancreatitis. JAMA Intern Med 2016; 176: 1834–42 CrossRef MEDLINE
8. Ference BA, Kastelein JJP, Ray KK, et al.: Association of triglyceride- lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. JAMA 2019; 321: 364–73 CrossRef MEDLINE PubMed Central
9.Varbo A, Benn M, Tybjaerg-Hansen A, et al.: Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 2013; 6: 427–36 CrossRef MEDLINE
10. Nordestgaard BG, Benn M, Schnohr P, et al.: Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298: 299–308 CrossRef MEDLINE
11. Tushuizen ME, Diamant M, Heine RJ: Postprandial dysmetabolism and cardiovascular disease in type 2 diabetes. Postgrad Med J 2005; 81: 1–6 CrossRef MEDLINE PubMed Central
12. Zilversmit DB: Atherogenesis: a postprandial phenomenon. Circulation 1979; 60: 473–85 CrossRef MEDLINE
13. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502.
14. Nordestgaard BG, Langsted A, Mora S, et al.: Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J 2016; 37: 1944–58 CrossRef MEDLINE PubMed Central
15.NICE: National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification https://www.nice.org.uk/guidance/cg181/resources/cardiovascular-disease-risk-assessment-and-reduction-including-lipid-modification-pdf-35109807660997 (last accessed on 17 October 2019).
16. DEGAM: Hausärztliche Risikoberatung zur kardiovaskulären Prävention. S3-Leitlinie. AWMF-Register-Nr. 053–024 DEGAM-Leitlinie Nr. 19 https://www.degam.de/files/Inhalte/Leitlinien-Inhalte/Dokumente/DEGAM-S3-Leitlinien/053–024_Risikoberatung%20kardiovaskul.%20Praevention/053–024l_Hausärztliche_Risikoberatung_kardivaskuläre_Praevention_29–08–2018.pdf (last accessed on 17 October 2019).
17.Universitätsklinikum Leipzig — AöR: Merkblatt zur Ernährung für Patienten mit Hypertriglyzeridämie: https://www.uniklinikum-leipzig.de/einrichtungen/kardiologie/Freigegebene%20Dokumente/Merkblatt_Hypertriglyzeridämie.pdf (last accessed on 17 October 2019).
18. Piercy KL, Troiano RP, Ballard RM, et al.: The physical activity guidelines for americans. JAMA 2018; 320: 2020–8 CrossRef MEDLINE
19. Ference BA, Ginsberg HN, Graham I, et al: Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017; 38: 2459–72 CrossRef MEDLINE PubMed Central
20. Parhofer, KG: The treatment of disorders of lipid metabolism. Dtsch Arztebl Int 2016; 113: 261–8 CrossRef MEDLINE PubMed Central
21. Cholesterol Treatment Trialists (CTT) Collaboration, Baigent C, Blackwell L, et al.: Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670–81 CrossRef
22. Ast M, Frishman WH: Bile acid sequestrants. J Clin Pharmacol 1990; 30: 99–106 CrossRef MEDLINE
23. Katsiki N, Nikolic D, Montalto G, et al.: The role of fibrate treatment in dyslipidemia: an overview. Curr Pharm Des 2013; 19: 3124–31 CrossRef MEDLINE
24. Wang D, Liu B, Tao W, et al.: Fibrates for secondary prevention of cardiovascular disease and stroke. Cochrane Database Syst Rev 2015: CD009580 CrossRef PubMed Central
25. Rubins HB, Robins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410–8 CrossRef MEDLINE
26. ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, et al.: Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1563–74 CrossRef MEDLINE PubMed Central
27. Jun M, Foote C, Lv J, et al.: Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010; 375: 1875–84 CrossRef
28. Araki E, Yamashita S, Arai H, et al: Effects of Pemafibrate, a novel selective PPARalpha modulator, on lipid and glucose metabolism in patients with type 2 Diabetes and hypertriglyceridemia: A randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2018; 1: 538–46 CrossRef MEDLINE
29. [No authors listed]: Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopr MEDLINE vvivenza nell‘Infarto miocardico. Lancet 1999; 354: 447–55 CrossRef
30. Aung T, Halsey J, Kromhout D, et al.: Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: Meta-analysis of 10 trials involving 77917 individuals. JAMA Cardiol 2018; 3: 225–34 CrossRef PubMed Central
31.Manson JE, Cook NR, Lee IM, et al.: Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med 2019; 380: 23–32 CrossRef CrossRef
32. Bhatt DL, Steg PG, Miller M, et al.: Cardiovascular risk reduction with Icosapent ethyl for hypertriglyceridemia. N Engl J Med 2019; 380: 11–22 CrossRef MEDLINE
33.Nicholls SJ, Lincoff AM, Bash D, et al.: Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial. Clin Cardiol 2018; 41: 1281–8 CrossRef MEDLINE PubMed Central
34.Parhofer KG. New approaches to address dyslipidemia. Curr Opin Lipidol 2017; 28: 452–7 CrossRef MEDLINE
35. Witztum JL, Gaudet D, Freedman SD, et al.: Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N Engl J Med 2019; 381: 531–42 CrossRef MEDLINE
36. Lennertz A, Parhofer KG, Samtleben W, Bosch T: Therapeutic plasma exchange in patients with chylomicronemia syndrome complicated by acute pancreatitis. Ther Apher 1999; 3: 227–33 CrossRef MEDLINE
37. Berberich AJ, Ziada A, Zou GY, et al.: Conservative management in hypertriglyceridemia-associated pancreatitis. J Intern Med 2019; doi: 10.1111/joim.12925 CrossRef MEDLINE
38. Mizushima T, Ochi K, Matsumura N, et al.: Prevention of hyperlipidemic acute pancreatitis during pregnancy with medium-chain triglyceride nutritional support. Int J Pancreatol 1998; 23: 187–92.
39. Bolla D, Schyrba V, Drack G, Schöning A, Stage A, Hornung R: Chylomicronemia syndrome in pregnancy: a case report of an acute necrotizing pancreatitis. Geburtshilfe Frauenheilkd 2012; 72: 853–5 CrossRef MEDLINE PubMed Central
40. Blom DJ, O‘Dea L, Digenio A, et al.: Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study. J Clin Lipidol 2018; 12: 1234–43.e5 CrossRef MEDLINE
e1. Retterstol K, Narverud I, Selmer R, et al.: Severe hypertriglyceridemia in Norway: prevalence, clinical and genetic characteristics. Lipids Health Dis 2017; 16: 115 CrossRef MEDLINE PubMed Central
e2. Parhofer KG, Barrett PH, Schwandt P: Atorvastatin improves postprandial lipoprotein metabolism in normolipidemlic subjects. J Clin Endocrinol Metab. 2000; 85: 4224–30 CrossRef CrossRef MEDLINE
e3.Stroes E, Moulin P, Parhofer KG, et al.: Diagnostic algorithm for familial chylomicronemia syndrome. Atheroscler Suppl 2017; 23: 1–7 CrossRef MEDLINE
e4. Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, et al.: Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302: 1993–2000 CrossRef MEDLINE PubMed Central
e5. Boekholdt SM, Arsenault BJ, Mora S, et al.: Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 2012; 307: 1302–9 CrossRef MEDLINE
e6.Rimm EB, Williams P, Fosher K, Criqui M, Stampfer MJ: Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. BMJ 1999; 319: 1523–8 CrossRef MEDLINE PubMed Central
e7. Santos FL, Esteves SS, da Costa Pereira A, Yancy WS Jr, Nunes JP: Systematic review and meta-analysis of clinical trials of the effects of low carbohydrate diets on cardiovascular risk factors. Obes Rev 2012; 13: 1048–66 CrossRef MEDLINE
e8.Shaw K, Gennat H, O‘Rourke P, DelMar C.: Exercise for overweight or obesity. Cochrane Database Syst Rev 2006: CD003817 CrossRef
e9.Zomer E, Gurusamy K, Leach R, et al.: Interventions that cause weight loss and the impact on cardiovascular risk factors: a systematic review and meta-analysis. Obes Rev 2016; 17: 1001–11 CrossRef MEDLINE
e10. Cannon CP, Blazing MA, Giugliano RP, et al.: Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387–97 CrossRef MEDLINE
e11. Sabatine MS, Giugliano RP, Keech AC, et al.: Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713–22 CrossRef MEDLINE
e12. Schwartz GG, Steg PG, Szarek M, et al.: Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018; 379: 2097–107 CrossRef MEDLINE
e13. Frick MH, Elo O, Haapa K, et al.: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237–45 CrossRef MEDLINE